{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:58:35Z","timestamp":1794315515334,"version":"4.9.0"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>There is an increased risk of malignancies in patients with many systemic rheumatic diseases, which negatively impact on their quality of life. The risk and types of malignancies can differ by the type of rheumatic diseases. Possible mechanisms linking them are dynamic and complicated, including chronic inflammation and damage in rheumatic disease, inability to clear oncogenic infections, shared etiology and some anti-rheumatic therapies. Although certain disease-modifying anti-rheumatic drugs (DMARDs) have been proved to be potentially carcinogenic, the majority of them were not associated with increased risk of most malignancies in patients with systemic rheumatic diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1095526","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T16:55:03Z","timestamp":1678121703000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Malignancies in systemic rheumatic diseases: A mini review"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhe","family":"Geng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38928","article-title":"Review: Cancer-induced autoimmunity in the rheumatic diseases","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202006020","article-title":"Systemic lupus erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann Intern Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170179","article-title":"Malignancy in pediatric-onset systemic lupus erythematosus","volume":"44","author":"Bernatsky","year":"2017","journal-title":"J Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2012.12.009","article-title":"Cancer risk in systemic lupus: An updated international multi-centre cohort study","volume":"42","author":"Bernatsky","year":"2013","journal-title":"J Autoimmun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2020.05.005","article-title":"Cancer and systemic lupus erythematosus","volume":"46","author":"Ladouceur","year":"2020","journal-title":"Rheum Dis Clin North Am"},{"key":"B6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s13075-018-1760-3","article-title":"The risks of cancer development in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis","volume":"20","author":"Song","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24425","article-title":"Cancer risk in a Large inception systemic lupus erythematosus cohort: Effects of demographic characteristics, smoking, and medications","volume":"73","author":"Bernatsky","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.23","article-title":"DNA-Damaging autoantibodies and cancer: The lupus butterfly theory","volume":"12","author":"Noble","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.berh.2016.03.001","article-title":"Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link","volume":"30","author":"Egiziano","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary sjogren's syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/art.39518","article-title":"Rheumatoid factor and disease activity are independent predictors of lymphoma in primary sjogren's syndrome","volume":"68","author":"Nocturne","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases: A meta-analysis","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch Intern Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13192","article-title":"Sjogren syndrome-associated lymphomas: An update on pathogenesis and management","volume":"168","author":"Nocturne","year":"2015","journal-title":"Br J Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.11.004","article-title":"Lymphocyte transformation and autoimmune disorders","volume":"12","author":"Tarella","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.04.006","article-title":"Risk, predictors, and clinical characteristics of lymphoma development in primary sjogren's syndrome","volume":"41","author":"Solans-Laque","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.08.007","article-title":"Lymphomagenesis in sjogren's syndrome: Predictive biomarkers towards precision medicine","volume":"18","author":"Goules","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.04.004","article-title":"Malignant lymphoma in primary sjogren's syndrome: An update on the pathogenesis and treatment","volume":"43","author":"Routsias","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103084","article-title":"Primary sjogren's syndrome is associated with increased risk of malignancies besides lymphoma: A systematic review and meta-analysis","volume":"21","author":"Zhong","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102987","article-title":"Cancer incidence in primary sjogren's syndrome: Data from the French hospitalization database","volume":"20","author":"Goulabchand","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010111","article-title":"Update on malignancy in myositis-Well-Established association with unmet needs","volume":"12","author":"Opinc","year":"2022","journal-title":"Biomolecules"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.06.005","article-title":"Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort","volume":"45","author":"Dobloug","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab166","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0199-z","article-title":"Amyopathic dermatomyositis: A concise review of clinical manifestations and associated malignancies","volume":"17","author":"Udkoff","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: Clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key357","article-title":"The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis","volume":"58","author":"Oldroyd","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152011","article-title":"Serum levels of anti-transcriptional intermediary factor 1-gamma autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis","volume":"55","author":"Zhang","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2021.10.003","article-title":"Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1gamma antibodies","volume":"104","author":"Ly","year":"2021","journal-title":"J Dermatol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222441","article-title":"Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1gamma autoantibodies","volume":"82","author":"Hosono","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150201","article-title":"Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence","volume":"132","author":"Fiorentino","year":"2022","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12016-015-8511-x","article-title":"Idiopathic inflammatory myopathies and malignancy: A comprehensive review","volume":"52","author":"Tiniakou","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1084\/jem.20041367","article-title":"Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy","volume":"201","author":"Casciola-Rosen","year":"2005","journal-title":"J Exp Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex413","article-title":"Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis","volume":"57","author":"Pinal-Fernandez","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00803-6","article-title":"Assessment of disease outcome measures in systemic sclerosis","volume":"18","author":"Lafyatis","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: A study from the EULAR scleroderma trials and research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24076","article-title":"Incidence, risk factors, and outcomes of cancer in systemic sclerosis","volume":"72","author":"Morrisroe","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00449","article-title":"Gene profiling in patients with systemic sclerosis reveals the presence of oncogenic gene signatures","volume":"9","author":"Dolcino","year":"2018","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes303","article-title":"Systemic sclerosis (scleroderma) and cancer risk: Systematic review and meta-analysis of observational studies","volume":"52","author":"Bonifazi","year":"2013","journal-title":"Rheumatol (Oxford)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-212999","article-title":"Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer","volume":"77","author":"Igusa","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.03.012","article-title":"Novel risk factors related to cancer in scleroderma","volume":"16","author":"Bernal-Bello","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03112","article-title":"Intriguing relationships between cancer and systemic sclerosis: Role of the immune system and other contributors","volume":"9","author":"Maria","year":"2018","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23173","article-title":"Inflammation and cancer: An ancient link with novel potentials","volume":"121","author":"Hussain","year":"2007","journal-title":"Int J Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00793-5","article-title":"Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions","volume":"18","author":"Komatsu","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(78)90071-1","article-title":"Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis","volume":"31","author":"Isomaki","year":"1978","journal-title":"J Chronic Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: A meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.03.011","article-title":"Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management","volume":"32","author":"De Cock","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"R61","DOI":"10.1186\/ar4498","article-title":"Cigarette smoking and risk of rheumatoid arthritis: A dose-response meta-analysis","volume":"16","author":"Di Giuseppe","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1250","article-title":"Smoking and lung cancer mortality in the united states from 2015 to 2065: A comparative modeling approach","volume":"169","author":"Jeon","year":"2018","journal-title":"Ann Intern Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072605","article-title":"Anti-inflammatory drugs as anticancer agents","volume":"21","author":"Zappavigna","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31388-6","article-title":"Esomeprazole and aspirin in barrett's oesophagus (AspECT): A randomised factorial trial","volume":"392","author":"Jankowski","year":"2018","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: A double-blind, randomised, placebo-controlled trial","volume":"395","author":"Burn","year":"2020","journal-title":"Lancet"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel396","article-title":"Non-hodgkin's lymphoma\u2013meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories","volume":"46","author":"Bernatsky","year":"2007","journal-title":"Rheumatol (Oxford)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.036459","article-title":"Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica\/giant cell arteritis","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.096925","article-title":"Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: Results from a case-control study","volume":"69","author":"Hellgren","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25408","article-title":"The non-conventional effects of glucocorticoids in cancer","volume":"231","author":"Azher","year":"2016","journal-title":"J Cell Physiol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: Golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"B60","article-title":"Methotrexate: From its introduction to non-oncologic therapeutics to anti-TNF-alpha","volume":"28","author":"Benedek","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.09.027","article-title":"Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review","volume":"158","author":"Wang","year":"2018","journal-title":"Eur J Med Chem"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01125.x","article-title":"Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil","volume":"5","author":"Robson","year":"2005","journal-title":"Am J Transplant"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000186382.81130.ba","article-title":"Malignancy after transplantation","volume":"80","author":"Buell","year":"2005","journal-title":"Transplantation"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2002.005371","article-title":"Does long term treatment with azathioprine predispose to malignancy and death in patients with systemic lupus erythematosus","volume":"63","author":"Nero","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/ard.47.12.988","article-title":"Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study","volume":"47","author":"Silman","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/s0049-0172(99)80026-2","article-title":"The incidence of cancer associated with the treatment of rheumatoid arthritis","volume":"29","author":"Beauparlant","year":"1999","journal-title":"Semin Arthritis Rheum"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/s0300-483x(02)00612-1","article-title":"Immunosuppressive drugs and cancer","volume":"185","author":"Vial","year":"2003","journal-title":"Toxicology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199811)41:11<1930::AID-ART6>3.0.CO;2-N","article-title":"No increased risk of malignancies and mortality in cyclosporin a-treated patients with rheumatoid arthritis","volume":"41","author":"van den Borne","year":"1998","journal-title":"Arthritis Rheum"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: A nationwide cohort study from Sweden","volume":"177","author":"Wadstrom","year":"2017","journal-title":"JAMA Intern Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209285","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: Results from a collaborative project of 11 European biologic registers","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200622","article-title":"The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: Longitudinal results from the British society for rheumatology biologics register","volume":"71","author":"Mercer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab570","article-title":"Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice","volume":"61","author":"Huss","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.22","article-title":"Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases","volume":"13","author":"Croft","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7254.2008.00889.x","article-title":"Tumor necrosis factor and cancer, buddies or foes","volume":"29","author":"Wang","year":"2008","journal-title":"Acta Pharmacol Sin"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30362-0","article-title":"Anti-tumour necrosis factor-alpha therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: A nationwide, population-based cohort study","volume":"5","author":"Waljee","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i262","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden","volume":"352","author":"Raaschou","year":"2016","journal-title":"BMJ"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: Nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: A systematic review","volume":"178","author":"Peleva","year":"2018","journal-title":"Br J Dermatol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ctrv.2016.11.015","article-title":"Rituximab: 13 open questions after 20years of clinical use","volume":"53","author":"Pavanello","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: A review in rheumatoid arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez604","article-title":"Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study","volume":"59","author":"de Germay","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B87","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.02.007","article-title":"Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis","volume":"47","author":"Maneiro","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.08.007","article-title":"Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies","volume":"50","author":"Xie","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: Results from the open-label, randomised controlled ORAL surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/art.42250","article-title":"Tofacitinib and risk of malignancy: Results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study","volume":"74","author":"Khosrow-Khavar","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B94","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.101472","article-title":"The relationships between cancer and autoimmune rheumatic diseases","volume":"34","author":"Cappelli","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102882","article-title":"Autoimmunity and cancer","volume":"20","author":"Masetti","year":"2021","journal-title":"Autoimmun Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1095526\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T16:55:06Z","timestamp":1678121706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1095526\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":96,"alternative-id":["10.3389\/fimmu.2023.1095526"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1095526","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"article-number":"1095526"}}